Table 4.

Contingency tables and mortality rates for the Zurich patient cohort

Estimated AKI stagesMDRD Model (Cohen κ: 0.40)CKD-EPI Model (Cohen κ: 0.38)
Measured AKI stages0123Sum0123Sum
 02539 (99.7)344 (84.3)49 (63.6)2 (2.2)293402507 (99.7)372 (85.3)53 (66.3)2 (2.2)2934
2.75.516.33.22.65.817.73.2
 17 (0.3)64 (15.7)24 (31.2)3 (3.3)9817 (0.3)64 (14.7)23 (28.8)4 (4.3)98
7.018.353.29.47.018.522.09.4
 2004 (5.2)042004 (5.0)04
 300087 (94.6)87300087 (93.5)87
39.439.439.439.4
Sum254640877923123Sum251443680933123
2.75.816.538.04.02.66.017.537.14.0
Estimated AKI stagesPLTV Model (Cohen κ: 0.27)eSCr Model (Cohen κ: 0.55)
Measured AKI stages0123Sum0123Sum
 02272 (100.0)591 (90.8)65 (64.4)6 (6.1)293402729 (99.3)185 (73.7)20 (55.6)02934
2.84.311.73.23.06.59.23.2
 1060 (9.2)33 (32.7)5 (5.1)98118 (0.7)66 (26.3)13 (36.1)1 (1.1)98
5.415.626.89.43.09.520.99.4
 2003 (3.0)1 (1.0)42003 (8.3)1 (1.1)4
 300087 (87.9)87300087 (97.8)87
39.439.439.439.4
Sum2272651101993123Sum274725136893123
2.84.412.934.14.03.07.413.138.24.0
  • Values are given as numbers (n), column percentages (%), mortality rates per 100 patient years (†), or Kidney Disease Improving Global Outcomes stages. MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; PLTV, Pittsburgh Linear Three Variables; eSCr, estimated serum creatinine.